FDA Staff Says Totality Of Available Evidence Suggests That A Monovalent XBB-Tailored Vaccine Is Warranted For The 2023–24 Vaccination Campaign; Current Subvariants Under Consideration For 2023-24 Vaccination Campaign Include XBB.1.5, XBB.1.16, Or XBB.2.3
Portfolio Pulse from Benzinga Newsdesk
The FDA staff suggests that a monovalent XBB-tailored vaccine is warranted for the 2023-24 vaccination campaign, with subvariants XBB.1.5, XBB.1.16, and XBB.2.3 under consideration.
June 12, 2023 | 2:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca may be impacted by the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 vaccination campaign.
As a vaccine manufacturer, AstraZeneca may benefit from the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 campaign if they develop and produce the vaccine.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
BioNTech may be impacted by the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 vaccination campaign.
As a vaccine manufacturer, BioNTech may benefit from the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 campaign if they develop and produce the vaccine.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Johnson & Johnson may be impacted by the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 vaccination campaign.
As a vaccine manufacturer, Johnson & Johnson may benefit from the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 campaign if they develop and produce the vaccine.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Moderna may be impacted by the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 vaccination campaign.
As a vaccine manufacturer, Moderna may benefit from the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 campaign if they develop and produce the vaccine.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Novavax may be impacted by the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 vaccination campaign.
As a vaccine manufacturer, Novavax may benefit from the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 campaign if they develop and produce the vaccine.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Pfizer may be impacted by the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 vaccination campaign.
As a vaccine manufacturer, Pfizer may benefit from the FDA's recommendation for a monovalent XBB-tailored vaccine for the 2023-24 campaign if they develop and produce the vaccine.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50